Saturday, 31 October 2026European Markets

COLRUYT Stock Bullish By 17% So Far Today

Loading stream...

(VIANEWS) - Shares of COLRUYT (BEL 20: COLR.BR) jumped by a staggering 17.2% to €29.51 at 11:14 EST on Wednesday, after two successive sessions in a row of losses. BEL 20 is jumping 0.07% to €3,762.94, following the last session's downward trend. This seems, up until now, a somewhat positive trend exchanging session today.

About COLRUYT

Etn. Fr. Colruyt NV, together with its subsidiaries, engages in the retail, wholesale, food service, and other activities in Belgium, France, and internationally. It operates through three segments: Retail, Wholesale and Foodservice, and Other Activities. The company operates CNG and hydrogen filling stations; provides printing and document management solutions; and develops, constructs, operates, and finances wind energy projects. In addition, the company provides fresh products, dry food, and frozen and non-food products. It provides its products and services to wholesalers, commercial customers, and affiliated independent merchants, as well as, schools, care homes, the hospitality sector, etc. The company was founded in 1928 and is headquartered in Halle, Belgium.

Earnings Per Share

As for profitability, COLRUYT has a trailing twelve months EPS of €1.64.

PE Ratio

COLRUYT has a trailing twelve months price to earnings ratio of 17.99. Meaning, the purchaser of the share is investing €17.99 for every euro of annual earnings.

More news about COLRUYT (COLR.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com